ArticleFrontiers in endocrinology2026
Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Roux-en-Y gastric bypass (RYGB) rapidly improves glycemic control in obesity and type 2 diabetes (T2D), but the underlying mechanisms remain incompletely understood. Chymotrypsin-like elastase family member 2A (CELA2A), a circulating pancreatic serine protease implicated in metabolic regulation, has been proposed to contribute to these effects, although its regulation in obesity and after metabolic surgery remains unclear. We investigated CELA2A expression in gastrointestinal tissues and circulation in relation to obesity and RYGB. Methods: Gastric biopsies were collected in a cross-cohort, non-paired comparison perioperatively from patients undergoing sleeve gastrectomy and postoperatively from patients after RYGB. Jejunal biopsies and serum samples were obtained in paired study setup before and after RYGB. Intestinal tissue and serum were also analyzed in mice fed a control or high-fat diet. CELA2A expression was assessed using Western blot, immunohistochemistry, and ELISA. Results: After RYGB, CELA2A expression increased in gastric mucosa but decreased in the jejunum, accompanied by reduced circulating CELA2A. Before surgery, jejunal CELA2A levels were positively associated with HbA1c, but not with fasting insulin. In high-fat diet-fed mice, jejunal CELA2A expression was increased, whereas gastric expression was reduced. Circulating CELA2A levels were not significantly altered in this model. In both species, CELA2A immunoreactivity was observed in mucosal glandular structures of the stomach and jejunum; however, detailed cellular localization in human tissue was not established, and circulating and tissue levels were not directly correlated. Conclusion: CELA2A exhibits tissue-specific regulation in obesity and following bariatric surgery and may represent a candidate component of gastrointestinal metabolic signaling. Further studies are required to define its cellular origin and functional role in glucose homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.